63 related articles for article (PubMed ID: 24938407)
1. MED12 overexpression is a frequent event in castration-resistant prostate cancer.
Adler D; Offermann A; Braun M; Menon R; Syring I; Nowak M; Halbach R; Vogel W; Ruiz C; Zellweger T; Rentsch CA; Svensson M; Andren O; Bubendorf L; Biskup S; Duensing S; Kirfel J; Perner S
Endocr Relat Cancer; 2014 Aug; 21(4):663-675. PubMed ID: 24938407
[TBL] [Abstract][Full Text] [Related]
2. Identification of DNA damage response-related genes as biomarkers for castration-resistant prostate cancer.
Oshima M; Takayama KI; Yamada Y; Kimura N; Kume H; Fujimura T; Inoue S
Sci Rep; 2023 Nov; 13(1):19602. PubMed ID: 37950047
[TBL] [Abstract][Full Text] [Related]
3. The KDM5 inhibitor PBIT reduces proliferation of castration-resistant prostate cancer cells via cell cycle arrest and the induction of senescence.
Smith T; White T; Chen Z; Stewart LV
Exp Cell Res; 2024 Apr; 437(1):113991. PubMed ID: 38462208
[TBL] [Abstract][Full Text] [Related]
4. Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer.
Meenu M; Verma VK; Seth A; Sahoo RK; Gupta P; Arya DS
Curr Ther Res Clin Exp; 2020; 93():100610. PubMed ID: 33245296
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of transforming growth factor-β-regulated long non-coding RNAs in prostate cancer pathogenesis.
Shree B; Das K; Sharma V
Cancer Pathog Ther; 2023 Jul; 1(3):195-204. PubMed ID: 38327834
[TBL] [Abstract][Full Text] [Related]
6. AID-induced CXCL12 upregulation enhances castration-resistant prostate cancer cell metastasis by stabilizing β-catenin expression.
Li Q; Fan J; Zhou Z; Ma Z; Che Z; Wu Y; Yang X; Liang P; Li H
iScience; 2023 Dec; 26(12):108523. PubMed ID: 38162032
[TBL] [Abstract][Full Text] [Related]
7. Mapping mutations in prostate cancer exomes.
Sunkel B; Wang Q
Asian J Androl; 2012 Nov; 14(6):801-2. PubMed ID: 22842706
[TBL] [Abstract][Full Text] [Related]
8. Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.
Kämpjärvi K; Kim NH; Keskitalo S; Clark AD; von Nandelstadh P; Turunen M; Heikkinen T; Park MJ; Mäkinen N; Kivinummi K; Lintula S; Hotakainen K; Nevanlinna H; Hokland P; Böhling T; Bützow R; Böhm J; Mecklin JP; Järvinen H; Kontro M; Visakorpi T; Taipale J; Varjosalo M; Boyer TG; Vahteristo P
Prostate; 2016 Jan; 76(1):22-31. PubMed ID: 26383637
[TBL] [Abstract][Full Text] [Related]
9. Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma.
Lim WK; Ong CK; Tan J; Thike AA; Ng CC; Rajasegaran V; Myint SS; Nagarajan S; Nasir ND; McPherson JR; Cutcutache I; Poore G; Tay ST; Ooi WS; Tan VK; Hartman M; Ong KW; Tan BK; Rozen SG; Tan PH; Tan P; Teh BT
Nat Genet; 2014 Aug; 46(8):877-80. PubMed ID: 25038752
[TBL] [Abstract][Full Text] [Related]
10. Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia.
Kämpjärvi K; Järvinen TM; Heikkinen T; Ruppert AS; Senter L; Hoag KW; Dufva O; Kontro M; Rassenti L; Hertlein E; Kipps TJ; Porkka K; Byrd JC; de la Chapelle A; Vahteristo P
Oncotarget; 2015 Jan; 6(3):1884-8. PubMed ID: 25595892
[TBL] [Abstract][Full Text] [Related]
11. Med12 gain-of-function mutation causes leiomyomas and genomic instability.
Mittal P; Shin YH; Yatsenko SA; Castro CA; Surti U; Rajkovic A
J Clin Invest; 2015 Aug; 125(8):3280-4. PubMed ID: 26193636
[TBL] [Abstract][Full Text] [Related]
12. Elf5 inhibits TGF-β-driven epithelial-mesenchymal transition in prostate cancer by repressing SMAD3 activation.
Yao B; Zhao J; Li Y; Li H; Hu Z; Pan P; Zhang Y; Du E; Liu R; Xu Y
Prostate; 2015 Jun; 75(8):872-82. PubMed ID: 25728398
[TBL] [Abstract][Full Text] [Related]
13. The Mediator complex of Caenorhabditis elegans: insights into the developmental and physiological roles of a conserved transcriptional coregulator.
Grants JM; Goh GY; Taubert S
Nucleic Acids Res; 2015 Feb; 43(4):2442-53. PubMed ID: 25634893
[TBL] [Abstract][Full Text] [Related]
14. Cyclin C mediates stress-induced mitochondrial fission and apoptosis.
Wang K; Yan R; Cooper KF; Strich R
Mol Biol Cell; 2015 Mar; 26(6):1030-43. PubMed ID: 25609094
[TBL] [Abstract][Full Text] [Related]
15. Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells.
Severson PL; Vrba L; Stampfer MR; Futscher BW
Mutat Res Genet Toxicol Environ Mutagen; 2014 Dec; 775-776():48-54. PubMed ID: 25435355
[TBL] [Abstract][Full Text] [Related]
16. Tracking the origin of metastatic prostate cancer.
Lindberg J; Kristiansen A; Wiklund P; Grönberg H; Egevad L
Eur Urol; 2015 May; 67(5):819-22. PubMed ID: 25246081
[TBL] [Abstract][Full Text] [Related]
17. MED12 mutation frequency in unselected sporadic uterine leiomyomas.
Heinonen HR; Sarvilinna NS; Sjöberg J; Kämpjärvi K; Pitkänen E; Vahteristo P; Mäkinen N; Aaltonen LA
Fertil Steril; 2014 Oct; 102(4):1137-42. PubMed ID: 25108465
[TBL] [Abstract][Full Text] [Related]
18. Missense mutations in exon 2 of the MED12 gene are involved in IGF-2 overexpression in uterine leiomyoma.
Di Tommaso S; Tinelli A; Malvasi A; Massari S
Mol Hum Reprod; 2014 Oct; 20(10):1009-15. PubMed ID: 25015674
[TBL] [Abstract][Full Text] [Related]
19. Emerging proteins involved in castration‑resistant prostate cancer via the AR‑dependent and AR‑independent pathways (Review).
Feng K; Liu C; Wang W; Kong P; Tao Z; Liu W
Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37732538
[TBL] [Abstract][Full Text] [Related]
20. Exosomal transfer of miR-548aq-3p confers cisplatin resistance
Shi Y; Zou Y; Guo Y; Liu Y; Wang Q
Am J Cancer Res; 2023; 13(5):1999-2012. PubMed ID: 37293147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
